中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

15 records (took 0.04 seconds)

    FACTOR VIII COMPLEX WITH XTEN AND VON WILLEBRAND FACTOR PROTEIN, AND USES THEREOF
    12.
    发明申请
    FACTOR VIII COMPLEX WITH XTEN AND VON WILLEBRAND FACTOR PROTEIN, AND USES THEREOF 有权

    公开(公告)号：US20220056108A1

    公开(公告)日：2022-02-24

    申请号：US17358142

    申请日：2021-06-25

    Applicant: Bioverativ Therapeutics Inc.

    Inventor： Ekta Seth CHHABRA ,  Tongyao LIU ,  Pei-yun CHANG ,  Robert T. PETERS ,  John KULMAN ,  Haiyan JIANG

    IPC: C07K14/755 ,  A61K47/55 ,  A61K38/36 ,  A61K38/37 ,  C07K16/00 ,  C12N15/11

    Abstract: The present invention provides a chimeric protein comprising a VWF protein comprising the D′ domain and D3 domain of VWF, one or more XTEN sequence, and a FVIII protein, wherein the VWF fragment, the XTEN sequence, or the FVIII protein are linked to or associated with each other. The chimeric protein can further comprise one or more Ig constant region or a portion thereof (e.g., an Fc region). A polypeptide chain comprising a VWF fragment of the invention binds to or is associated with a polypeptide chain comprising a FVIII protein linked to an XTEN sequence and the polypeptide chain comprising the VWF fragment can prevent or inhibit binding of endogenous VWF to the FVIII protein linked to the XTEN sequence. By preventing or inhibiting binding of endogenous VWF to the FVIII protein, which is a half-life limiting factor for FVIII, the VWF fragment can induce extension of half-life of the chimeric protein comprising a FVIII protein. The invention also includes nucleotides, vectors, host cells, methods of using the VWF fragment, or the chimeric proteins.

    METHODS OF USING A FIXED DOSE OF A CLOTTING FACTOR
    13.
    发明申请
    METHODS OF USING A FIXED DOSE OF A CLOTTING FACTOR 审中-公开

    公开(公告)号：US20200030420A1

    公开(公告)日：2020-01-30

    申请号：US16502352

    申请日：2019-07-03

    Applicant: BIOVERATIV THERAPEUTICS INC.

    Inventor： Haiyan JIANG ,  Lei DIAO ,  Shuanglian LI ,  Paula COBB

    IPC: A61K38/48 ,  A61K38/36 ,  C12N9/64

    Abstract: The present invention provides methods of administering a clotting factor by a fixed dosing regimen; methods of reducing, ameliorating, or preventing one or more symptoms of a bleeding disease or disorder; and a kit comprising a dotting factor useful for a fixed dosing regimen. While plasma-derived and recombinant clotting factor products allow hemophilia patients to live longer and healthier, hemophilia still remains one of the most costly and complex conditions to manage.

Patent Agency Ranking